MPO was one of the plasma biomarkers assessed as a potential novel indicator of doxorubicin-induced cardiotoxicity in breast cancer patients in a study of 17 patients with triple-negative breast cancer patients and 17 healthy individuals [95]. The gene discussed is MPO; the disease is breast cancer.